The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin

Clinical Cancer Research

Volumn 18, Issue 8, 2012, Pages 2230-2239

  Lemaire, Miguel ^a   Fristedt, Charlotte ^b   Agarwal, Prasoon ^b   Menu, Eline ^a   Van Valckenborgh, Els ^a   De Bruyne, Elke ^a   Österborg, Anders ^c   Atadja, Peter ^e   Larsson, Olle ^d   Axelson, Magnus ^c   Van Camp, Ben ^a   Jernberg Wiklund, Helena ^b   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CYCLIN B1; CYCLIN D2; CYCLIN DEPENDENT KINASE 6; CYCLIN E; PANOBINOSTAT; PICROPODOPHYLLIN; PROTEIN BCL 2; PROTEIN MCL 1; REGULATOR PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL ADHESION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; ENZYME MODIFICATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS;

ANIMALS; APOPTOSIS; CASPASE 8; CELL ADHESION; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION PROFILING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; PODOPHYLLOTOXIN; RECEPTOR, IGF TYPE 1; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84859822013     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1764     Document Type: Article

References (46)

1. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8. (Pubitemid 24230014)
2. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104: 607-18. (Pubitemid 38970551)
3. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005;44:194-203. (Pubitemid 41306648)
4. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-95. (Pubitemid 46572539)
5. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8. (Pubitemid 44395016)
6. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941-8. (Pubitemid 40446289)
7. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009;113:4614-26.
8. Nilsson K, Georgii-Hemming P, Spets H, Jernberg-Wiklund H. The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro. Curr Top Microbiol Immunol 1999;246:325-32; discussion 33.
9. Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006;42:1574-80. (Pubitemid 44118772)
10. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996;88:2250-8. (Pubitemid 26307929)
11. Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997;159:487-96. (Pubitemid 127493736)
12. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000;111:626-34.
13. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999;93:235-41. (Pubitemid 29019408)
14. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997;97:429-40. (Pubitemid 27224626)
15. Ogawa M, Nishiura T, Oritani K, Yoshida H, Yoshimura M, Okajima Y, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000;60:4262-9. (Pubitemid 30636615)
16. Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004;103:3138-47. (Pubitemid 38451692)
17. Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006;107:669-78. (Pubitemid 43076393)
18. Jernberg-Wiklund H, Nilsson K. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Adv Cancer Res 2007;97:139-65. (Pubitemid 46541692)
19. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236-42. (Pubitemid 38114104)
20. Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 2007;121:1857-61. (Pubitemid 47417307)
21. Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006;107:655-60. (Pubitemid 43076391)
22. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99. (Pubitemid 37361445)
23. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-9.
24. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res 2011;35:373-9.
25. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006;66:5781-9. (Pubitemid 43927132)
26. Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, et al.Polycomb target genes are silenced in multiple myeloma. PLos One 2010;5:e11483.
27. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997;76:451-60. (Pubitemid 27331209)
28. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000;1:351-6.
29. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 2003;194:196-206. (Pubitemid 36896125)
30. Radl J, De Glopper ED, Schuit HR, Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979;122:609-13. (Pubitemid 9089221)
31. Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, Gorus F, et al. The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med 2005;113:191-205.
32. Matsuoka Y, Moore GE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 1967;125: 1246-50.
33. Karpas A, Fisher P, Swirsky D. Human plasmacytoma with an unusual karyotype growing in vitro and producing light-chain immunoglobulin. Lancet 1982;1:931-3. (Pubitemid 12146358)
34. Pegoraro L, Malavasi F, Bellone G, Massaia M, Boccadoro M, Saglio G, et al. The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood 1989;73:1020-7. (Pubitemid 19078382)
35. Katagiri S, Yonezawa T, Kuyama J, Kanayama Y, Nishida K, Abe T, et al. Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer 1985;36:241-6. (Pubitemid 15243451)
36. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
37. O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000;267:5421-6.
38. Vindelov LL. Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei. Virchows Arch B Cell Pathol 1977; 24:227-42. (Pubitemid 8159760)
39. De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood;115:2430-40.
40. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 2009;8:2122-30.
41. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy formultiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30. (Pubitemid 38402114)
42. Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia-Echeverria C, et al. Synergistic action of the novel HSP90 inhibitor NVPAUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010;84:337-44.
43. Hashemi J, Worrall C, Vasilcanu D, Fryknas M, Sulaiman L, Karimi M, et al. Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS One 2011;6:e14757.
44. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15:3958-69.
45. Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K. The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res 2011;110:19-42.
46. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-7. (Pubitemid 351380120)